ESC 365 - Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy

HFA Premium Access

Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy

Session: Heart failure with preserved ejection fraction (HFpEF) 1

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor A. Nalbandian (New York, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Ani Nalbandian

Columbia University Irving Medical Centre, New York (United States of America)

0 follower

7 more presentations in this session

Impact of temporary LV systolic dysfunction on long-term clinical outcome in patients with preserved ejection fraction after acute myocardial infarction

Speaker: Doctor J. Kim (Seoul, KR)

Vascular stiffness, cardiac chamber stiffness and cardiovascular risk factors in women versus men with pre-HFpEF; a report from the PARABLE trial.

Speaker: Doctor B. Wong (Dublin, IE)

Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction

Speaker: Doctor A. Aimo (Pisa, IT)

Coronary microvascular dysfunction, central and overall obesity and metabolic and fibrotic biomarkers in patients with heart failure with preserved ejection fraction (data from PROMIS-HFpEF)

Speaker: Mr M. Erhardsson (Stockholm, SE)

The prognostic value of hypoxemic burden measured by overnight oximetry in heart failure patients with preserved ejection fraction

Speaker: Miss S. Mourmans (Maastricht, NL)

Access the full session

Heart failure with preserved ejection fraction (HFpEF) 1

Speakers: Doctor A. Nalbandian, Doctor J. Kim, Doctor B. Wong, Doctor A. Aimo, Mr M. Erhardsson...

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources